U.S. Life Sciences Stock News

ALT5 Sigma (NasdaqCM:ALTS) has just posted a sharp swing in its FY 2025 third quarter numbers, with total revenue at US$7.6 million and Basic EPS at US$0.64, backed by net income from continuing operations of US$46.7 million and earnings from discontinued operations of US$2.3 million. Over recent quarters the company has seen revenue move from US$4.9 million in FY 2024 Q3 to US$5.4 million in Q4, US$5.5 million in FY 2025 Q1 and US$6.4 million in Q2. Quarterly EPS has ranged from a loss of...

Over the last 7 days, the United States market has risen by 3.1%, contributing to a substantial 27% climb over the past year, with earnings forecasted to grow by 16% annually. In such a robust market environment, growth companies with high insider ownership can be particularly attractive as they often indicate strong confidence from those closest to the business operations and future prospects.

The United States market has been on an upward trajectory, climbing 3.1% in the past week and 27% over the last year, with earnings projected to grow by 16% annually. In this dynamic environment, identifying stocks that combine strong fundamentals with growth potential can uncover promising opportunities for investors seeking to enhance their portfolios.

Over the last 7 days, the United States market has risen by 3.1%, contributing to a remarkable 27% increase over the past year, with earnings expected to grow by 16% annually in the coming years. In such a dynamic environment, reliable dividend stocks that offer attractive yields can provide investors with both income and potential growth opportunities.

KalVista Pharmaceuticals recently reported interim results from its KONFIDENT-KID trial, showing EKTERLY (sebetralstat) delivered rapid, well-tolerated oral treatment for hereditary angioedema attacks in children aged 2–11, with no serious or treatment-related adverse events. The trial, now the largest pediatric hereditary angioedema study and completed enrollment a year early, highlights strong clinical interest in a first-in-class oral option for a population currently limited to...

If you are wondering whether Magnite's current share price reflects its true worth, this breakdown will help you separate price from value. With the stock at US$11.98, recent returns have been mixed, including a 1.5% decline over 7 days, a 0.8% gain over 30 days, a 25.4% decline year to date, and a 23.8% gain over 1 year, while the 5 year return sits at a 66.8% decline. These moves sit against a longer track record that includes a 24.4% gain over 3 years, which can shape how investors think...

The United States market has shown robust performance, rising 3.1% over the last week and climbing 27% in the past year, with earnings projected to grow by 16% annually. In this environment, identifying stocks that are perceived as undervalued can be particularly appealing, especially when insider actions suggest confidence in their potential.

The United States market has shown robust performance, rising 3.1% over the last week and 27% over the past year, with earnings projected to grow by 16% annually. In such a thriving environment, identifying stocks that are potentially undervalued can offer opportunities for investors seeking to capitalize on discrepancies between current stock prices and their intrinsic values.

Over the last 7 days, the United States market has risen by 3.1%, contributing to a robust 27% increase over the past year, with earnings projected to grow by 16% annually in the coming years. In this thriving environment, identifying growth companies with strong insider ownership can be key as it often signals confidence in their long-term potential and alignment of interests between management and shareholders.

The United States market has shown robust performance, climbing 3.1% over the last week and 27% over the past year, with earnings projected to grow by 16% annually. In this context of market growth, identifying stocks with strong financials can be crucial for investors seeking potential opportunities. Penny stocks, though often seen as a term from earlier market days, still represent a segment where smaller or newer companies might offer both affordability and significant growth potential.

The United States market has shown robust performance, rising 3.1% over the last week and climbing 27% in the past year, with anticipated annual earnings growth of 16% in the years ahead. In this thriving environment, identifying stocks that offer unique value propositions and strong potential for growth can be key to uncovering hidden opportunities.

The Morning Bull - US Market Morning Update Monday, Apr, 13 2026 US stock futures are pointing lower this morning, with E-mini S&P 500 contracts down about 0.6% and Nasdaq 100 futures weaker by roughly 0.7%, as investors react to a fresh inflation shock and higher energy costs. March US consumer prices rose 0.9% month on month, while energy prices are up 12.5% over the past year, signaling that everyday costs from fuel to utilities remain under pressure. Brent crude above US$102 adds to...

Grace Therapeutics, Inc. ( NASDAQ:GRCE ) is possibly approaching a major achievement in its business, so we would like...

Rapid7, Inc. ( NASDAQ:RPD ), might not be a large cap stock, but it saw significant share price movement during recent...

Zentalis Pharmaceuticals (ZNTL) has drawn fresh investor attention after selecting a 400mg once daily, 5-days-on, 2-days-off azenosertib regimen as the optimal monotherapy dose in platinum resistant ovarian cancer. See our latest analysis for Zentalis Pharmaceuticals. The azenosertib update has arrived alongside intense trading interest, with a 1 day share price return of 49.55% and a year to date share price return of 382.48%. The 1 year total shareholder return sits at 437.40%, but the 3...

Ausbil Investment Management has disclosed H2O America (NasdaqGS:HTO) as its largest portfolio holding. ATLAS Infrastructure Partners has reported owning more than 10% of H2O America. These institutional ownership changes highlight a shift in H2O America's shareholder base that has not been widely discussed. For you as an investor, concentrated positions like Ausbil’s and a stake of more than 10% from ATLAS Infrastructure Partners can change how H2O America is viewed in the market. Large,...

U.S. Representative Gilbert Ray Cisneros, Jr. recently disclosed a personal purchase of Cathay General Bancorp (NasdaqGS:CATY) shares. The transaction adds a new political figure to the shareholder base of Cathay General Bancorp, which has previously drawn attention for executive insider activity. The purchase comes with Cathay General Bancorp shares trading around $53.47. Cathay General Bancorp, trading under NasdaqGS:CATY, has seen its shares at about $53.47, with recent returns of 5.7%...

IMAX (NYSE:IMAX) announced that CEO Richard Gelfond has taken a temporary medical leave of absence. The company has described the move as temporary, with existing leadership expected to oversee operations during his absence. IMAX runs a global network of premium large format cinemas and technology partnerships, placing it at the center of the theatrical side of the film industry. The company is closely tied to major studio release schedules and audience demand for big screen experiences...

Lotus Technology Inc. has reported its fourth-quarter and full-year 2025 results, with revenue falling to US$163.34 million for the quarter and US$519.10 million for the year, while net losses narrowed to US$85.77 million and US$464.22 million respectively compared with the prior year. Against this backdrop of shrinking sales but smaller losses, Lotus has also launched its new “For Me” hyper SUV in Beijing, showcasing its X-Hybrid Architecture and underscoring a push toward high-performance...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

We wouldn't blame Box, Inc. ( NYSE:BOX ) shareholders if they were a little worried about the fact that Eliahu...

Neogen has agreed to sell its Genomics business to Zoetis as part of a wider portfolio reshaping. The company has completed the divestiture of its Cleaners and Disinfectants business. Neogen is implementing a major restructuring, including a 10% global headcount reduction. These actions concentrate the business around its core Food Safety segment and streamline operations. For investors watching NasdaqGS:NEOG, these moves come after a mixed share price history. The stock is at $9.42, with a...

If you are wondering whether Jazz Pharmaceuticals at around US$194.20 is still offering value after a strong run, the key is to look closely at what the current price actually reflects. The stock has posted returns of 3.9% over the last 7 days, 8.8% over 30 days, 12.2% year to date, and 93.2% over the past year, which naturally raises questions about how much of the story is already priced in and how risk is being perceived. Recent attention on Jazz Pharmaceuticals has centered on its...

Medpace Holdings (NasdaqGS:MEDP) is facing multiple shareholder class action lawsuits tied to alleged false and misleading statements about its book to bill ratio and backlog cancellation rates. Investors claim they suffered losses after company disclosures, with recent insider stock sales by the CEO shortly before negative updates adding to concerns. The litigation focuses on whether management provided overly optimistic projections that did not align with internal business conditions. For...